{"id":786,"date":"2015-10-21T12:59:00","date_gmt":"2015-10-21T16:59:00","guid":{"rendered":"https:\/\/med.sites.unc.edu\/cfpulmcenter\/directory\/silvia-m-kreda-phd-2\/"},"modified":"2025-03-27T09:51:33","modified_gmt":"2025-03-27T13:51:33","slug":"silvia-m-kreda-phd","status":"publish","type":"directory","link":"https:\/\/www.med.unc.edu\/marsicolunginstitute\/directory\/silvia-m-kreda-phd\/","title":{"rendered":"Silvia M. Kreda, PhD"},"content":{"rendered":"

<\/p>\n

Specialty Areas:<\/h2>\n

Oligonucleotide-based therapeutic strategies for lung diseases. Delivery of therapeutic oligonucleotides to the lung and other non-hepatic organs. Targeting of therapeutic molecules to the airway epithelium. Regulation of mucin secretion in lung diseases.<\/p>\n

Research Focus:<\/h2>\n

Dr. Kreda\u2019s laboratory studies mechanisms of delivery of therapeutic molecules in the lung. The main goal is to develop novel and efficient delivery strategies of therapeutic nucleic acids in obstructive lung diseases. The Kreda laboratory is currently involved in designing an efficacious oligonucleotide-based therapeutic approach to correct cystic fibrosis mutations in patients resilient to modulator therapies (press release June 2021<\/a>) and orphan mutations that cause primary ciliary dyskinesia (PCD). The PCD studies have recently received funding from the Eshelman Institute for Innovation (see the following links: Silvia M. Kreda to Study Novel Therapeutic Strategy for Primary Ciliary Dyskinesia<\/a>\u00a0and Funded Projects – The Eshelman Institute for Innovation<\/a> [in the 2022 tab]) and NC TraCS (see the following links: NC TraCS Award Announcements<\/a> and Kreda, Leigh, & Ostrowski Selected for SOM Translational Team Science Award<\/a>). The laboratory uses state-of-the art technologies and patient-oriented models for precision and personalized medicine approaches.<\/p>\n

Dr. Kreda\u2019s research focuses also on identifying signaling molecules\/pathways that regulate airway mucin secretion. The main goal is to uncover potential targets of clinical interest to control abnormal luminal mucus accumulation in lung diseases. Her laboratory has developed and optimized in vitro and in vivo models of lung diseases with excessive mucus production and quantitative assays for therapeutic drug testing and evaluation of mucin production in airway epithelia.<\/p>\n

Dr. Kreda\u2019s laboratory and scientific studies are fully funded by competitive grants from different sources including the National Institutes of Health (NIH), Cystic Fibrosis Foundation<\/a>, NCTraCS (the NIH CTSA at UNC-CH), Eshelman Institute for Innovation, Initos Pharmaceuticals, AstraZeneca, and Forest Research Institute (now AstraZeneca). Her lab has successful collaborations with scientists from academic and pharmaceutical institutions to develop and test novel drugs for their potential therapeutic use in obstructive lung diseases. For more information contact Dr. Kreda<\/a>.<\/p>\n

Chronology:<\/h2>\n